Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. (NYSE: STVN) is a global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences companies. Its news flow, as reflected in recent press releases and SEC filings, centers on financial performance, capacity expansion, financing arrangements, and participation in healthcare investor conferences.
Investors following STVN news will find regular quarterly earnings announcements detailing revenue trends, segment performance for the Biopharmaceutical and Diagnostic Solutions and Engineering segments, margin evolution, and the growing contribution of high-value solutions such as high-performance Nexa® syringes and EZ-fill® vials and cartridges. These updates often include discussion of non-GAAP measures, capital expenditures, and liquidity.
News coverage also highlights strategic investments and footprint optimization, including expansions at manufacturing facilities in Cisterna di Latina and Fishers to increase pre-filled syringe and ready-to-use cartridge capacity, and enhancements at the Bad Oeynhausen, Germany, site for drug delivery system production. Financing news, such as the €200 million agreements with BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM, provides additional context on how Stevanato Group funds these projects.
In addition, Stevanato Group frequently announces its participation in major healthcare and investor conferences in locations such as New York, London, Las Vegas, Chicago, and Vienna. These events offer further insight into management’s views on market dynamics, high-value solutions, and long-term strategy.
By monitoring this page, readers can track Stevanato Group’s latest earnings releases, operational updates on capacity expansion and optimization plans, financing developments, and investor relations activities, all drawn from company-issued news and regulatory communications.
Stevanato Group (NYSE:STVN) reported strong Q2 2025 financial results with revenue increasing 8% to €280.0 million. The company's high-value solutions represented 42% of total revenue, reaching €116.8 million. The Biopharmaceutical and Diagnostic Solutions (BDS) segment grew 10%, while the Engineering segment declined 2%.
Key financial metrics showed improvement with gross profit margin increasing 210 basis points to 28.1% and adjusted EBITDA margin rising 240 basis points to 23.2%. The company maintained its fiscal 2025 guidance, expecting revenue between €1.160-1.190 billion and adjusted diluted EPS of €0.50-0.54.
Stevanato Group (NYSE: STVN) has secured €200 million in financing through agreements with multiple banks to support its capital expenditure projects. The funding breakdown includes €100 million from BNL BNP Paribas, €50 million from CDP, and €50 million from Banco BPM.
The financing will support expansion projects at the company's facilities in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.). The funds will be used to enhance pre-filled syringe production, set up ready-to-use (RTU) cartridge capacity, and complete device manufacturing construction, supporting the company's growing biologics programs.
Stevanato Group (NYSE: STVN), a leading provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, at 6:30 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Management will reference a slide presentation available on the company's Investor Relations website. Participants can pre-register for immediate access or join through various dial-in numbers provided for Italy, United Kingdom, and United States.
Stevanato Group (NYSE: STVN), a leading provider of drug containment, delivery, and diagnostic solutions, has announced its participation in three major investor conferences in May and June 2025:
- Bank of America Securities Healthcare Conference in Las Vegas - May 14, 2025, at 5:00 p.m. PT
- William Blair Growth Stock Conference in Chicago - June 4, 2025, at 1:20 p.m. CT
- Jefferies Global Healthcare Conference in New York City - June 5, 2025, at 10:30 a.m. ET
Live webcasts will be available on the company's website under the "Investors" section, with replays accessible for approximately 90 days after each event.
Stevanato Group (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, at 6:30 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a management presentation with accompanying slides. These materials will be available on the company's Investor Relations website under the 'Financial Results' section.
Participants can access the call through pre-registration, direct dial-in numbers available for Italy, United Kingdom, and United States, or via a live webcast. A replay of the webcast will be archived for three months on the company's website.
Stevanato Group (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences industries, has announced its participation in the KeyBanc Capital Markets Healthcare Forum.
The event is scheduled for March 18-19, 2025, with the company's presentation set for Tuesday, March 18, at 3:00 p.m. ET. Investors and interested parties can access the live webcast through the 'Investors' section of Stevanato's website at www.stevanatogroup.com. The presentation recording will remain available for approximately 90 days following the event.
Stevanato Group (NYSE: STVN) reported record revenue of €1,104 million for fiscal year 2024, marking a 2% increase from the previous year. The company's fourth quarter revenue grew 3% to €330.6 million, with high-value solutions representing 40% of total revenue.
Key financial metrics for FY2024 include:
- Adjusted EBITDA margin of 23.5%
- Diluted EPS of €0.43 and adjusted diluted EPS of €0.48
- High-value solutions revenue increased 15% to €422.3 million
- Biopharmaceutical and Diagnostic Solutions segment grew 6% to €933.7 million
- Engineering segment declined 17% to €170.3 million
For 2025, the company projects revenue between €1,160-1,190 million, adjusted EBITDA of €293.0-306.3 million, and adjusted diluted EPS of €0.51-0.55.
Stevanato Group (NYSE: STVN), a leading provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 6, 2025, at 6:30 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Management will reference a slide presentation available on the company's Investor Relations website. Participants can pre-register for immediate access to the call, while a live webcast will also be available. The webcast recording will be archived for three months on the company's Investor Relations section.
Stevanato Group (NYSE: STVN), a global leader in drug containment and delivery solutions for pharmaceutical, biotechnology, and life sciences industries, has announced its participation in the CJS Securities 25th Annual "New Ideas for the New Year" Investor Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 8:00 a.m. ET.
The company will provide a live webcast of the event through their website at www.stevanatogroup.com in the "Investors" section. Interested parties who cannot attend the live presentation can access a replay of the webcast, which will remain available for approximately 90 days following the event.